“Data from preclinical sickle cell disease models suggest that blockade of P-selectin effectively prevents the painful stoppage of circulation in small blood vessels called vasoocclusion and maintains patent blood flow,” said Selexys Executive Vice President Dr. Russell Rother. “Results from our recently completed Phase I study indicate that SelG1 is well tolerated in healthy human subjects.
“We now look forward to investigating its safety and efficacy in the sickle cell disease patient population.”
With the limited therapies available to patients with sickle cell disease, this trial with a novel P-selectin inhibitor is particularly exciting.”
Dr. Kenneth Ataga,
Lead investigator and a professor at the University of North Carolina at Chapel Hill